MOTS-c dosing — commonly cited research pattern

There is no established human dose of MOTS-c. There are only three places a number could originate: mouse experiments, a registered clinical protocol, and community reports. The mouse work in the 2015 Cell Metabolism discovery paper (PMID 25738459) administered the peptide to rodents and measured metabolic outcomes, but rodent milligram-per-kilogram figures do not convert into human amounts without pharmacokinetic data that has never been published for MOTS-c in people. The human observational studies (PMID 34351816, PMID 31066084) contain no dose at all, because they only measured endogenous levels.

That leaves one protocol and a lot of forum arithmetic.

A phase 2a randomized, double-blind, placebo-controlled study sponsored by Hudson Biotech (NCT07505745) is recruiting an estimated 120 adults aged 18–65 with prediabetes and a BMI of 27.0–40.0 kg/m². Its stated design:

• Route — subcutaneous injection.
• Frequency — once daily.
• Duration — 12 weeks of treatment, plus a 4-week safety follow-up.
• Comparator — matching placebo.
• Co-primary outcomes — change in OGTT-derived insulin sensitivity (Matsuda index) at 12 weeks, and treatment-emergent adverse events through 16 weeks.

Note the schedule: daily, for three months. That is a structurally different regimen from the intermittent pattern circulating in community material, and it comes from the only group that has designed a study to find out whether administered MOTS-c does anything in a person. No results have been posted, and a registered protocol is a hypothesis about dosing, not a validated one.

Reported figures, all anecdotal and untraceable to any published study:

• Roughly 5–10 mg, two to three times per week.
• Short cycles of several weeks rather than continuous use.
• Start-low framing based on general caution, not on any dose-response data.

These describe what people report doing. They should not be read as validated amounts, and the divergence from the registered protocol's daily schedule is a useful illustration of how far community schemas can sit from a designed study.

In research settings MOTS-c is supplied as a lyophilized powder and reconstituted before subcutaneous injection; as a 16-residue peptide it is degraded if swallowed. Two handling facts drive most real-world error:

• The delivered amount depends on reconstitution — how much diluent goes into the vial sets the concentration, and syringe units measure volume rather than milligrams.
• Sterility, cold storage, and protection from heat, light, and freeze-thaw all affect what remains in solution.

A separate problem sits upstream: material sold as research-grade MOTS-c has no verified potency, so the milligram figure on a label is an assertion rather than a measurement.

MOTS-c acts on glucose and energy metabolism through AMPK activation (PMID 25738459), and under metabolic stress it enters the nucleus to regulate gene expression (PMID 29983246) — pathways where the appropriate exposure pattern is exactly the kind of question a phase 2 trial exists to answer. The registered study excludes participants with diabetes, recent cardiovascular events, and significant renal or hepatic disease, which indicates where its designers placed the uncertainty. With no approved label and no published human dose-response, any concrete decision belongs with qualified clinical judgment rather than with a figure from a forum.